Loading company…
Suzhou Keyin Biomedical uses AI technology to research and develop new drugs.
Founded in 2020 and based in Suzhou, China, Suzhou Keyin Biomedical develops drugs using AI technology. Its de novo drug design platform explores chemical space and supports virtual discovery for new targets. The team focuses on early-stage tumor and immunity targets and small-molecule drugs. In August 2021, the company raised more than RMB 10 million in Series A funding, led by Sherpa Venture Capital with participation from Frees Fund.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in